Heterocyclic Compounds

Matches 151 - 200 out of 33,986	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/042361A1	TYK2 INHIBITORS AND USES THEREOF Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...
WO/2024/041460A1	NOVEL NLRP3 INFLAMMASOME INHIBITORS The present invention provides compounds of Formula (I) : wherein all of the variables are as defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for the...
WO/2024/043341A1	CYCLOALKYNE DERIVATIVE The present invention provides a novel strain-promoted azide-alkyne cycloaddition (SPAAC) reaction. The present invention also provides a novel cycloalkyne derivative having a spiro ring as a cycloalkyne derivative that can be used in SP...
WO/2024/042147A2	NOVEL DEUTERATED PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES The invention relates to novel compounds having the general formula (I) wherein the substituents R1, R2, R3, R4 and X1 are as defined above, composition including the compounds and methods of using the compounds.
WO/2024/042544A1	NICKEL-BASED CATALYSTS FOR THE SELECTIVE (DE)HYDROGENATIVE COUPLING OF BENZYL ALCOHOLS WITH AZOBENZENES The present disclosure discloses a nickel catalyst of formula (I). The present disclosure also discloses a process of hydrogenation-dehydrogenation coupling catalyzed by catalyst of formula (I). Further, the present disclosure also discl...
WO/2024/041589A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND USE THEREOF Disclosed are a nitrogen-containing heterocyclic compound, a preparation method therefor, an intermediate thereof, and use thereof. Specifically, the present invention provides a nitrogen-containing heterocyclic compound as represented b...
WO/2024/044344A1	PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY The invention provides pyridinylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
WO/2024/041183A1	ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS The present application relates to an organic compound, an organic electroluminescent device, and an electronic apparatus. The organic compound of the present application has a structure represented by formula (1). By applying the organi...
WO/2024/041608A1	CRYSTAL FORM OF HETEROARYL DERIVATIVE PARP INHIBITOR AND USE THEREOF The present invention relates to a crystal form of a compound N-cyclopropyl-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyri din-3-yl)methyl)piperazin-1-yl)pyridine carboxamide and a preparation method therefor, and the use thereof in the ...
WO/2024/042480A1	HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS The present invention relates to heteroaromatic compounds of formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof as antagonist at serotonin 5-HT2A receptor and agonist at serotonin 5-HT1A rec...
WO/2023/073641A9	ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS This invention provides for compounds of the formula: (I) wherein the variables are defined herein, or salt thereof, compositions comprising these compounds, and methods for the treatment, control and/or prevention of a parasitic infesta...
WO/2024/041629A1	PREPARATION METHOD FOR R-TYPE KETOROLAC AND USE THEREOF The present invention provides a preparation method for R-type ketorolac and use thereof, and belongs to the technical field of organic synthesis. The preparation method comprises the following steps: step 1, preparing ketorolac; and ste...
WO/2024/044730A1	PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY The invention provides pyrazolylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
WO/2024/042007A1	SUBSTITUTED BICYCLES AS HSET INHIBITORS The invention relates to substituted bicycles of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative diseases and disorders in mammals, especially humans,...
WO/2024/042494A1	SUBSTITUTED PYRROLOTRIAZINES The inventive compounds are small molecule therapeutics that are potent inhibitors of USP7 activity. The invention also provides pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or pr...
WO/2024/041614A1	SOLID FORMS COMPRISING (S) -7- (1-ACRYLOYLPIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHYDROPYRAZOLO [1, 5-A] PYRIMIDINE-3-CARBOXAMIDE, AND OXALIC ACID, COMPOSITIONS AND METHODS OF USE THEREOF Provided herein are formulations, processes, solid forms and methods of use relating to (S) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a]pyrimidine-3-carboxamide.
WO/2024/041605A1	PHARMACEUTICALLY ACCEPTABLE SALT OF HETEROARYL DERIVATIVE PARP INHIBITOR AND USE THEREOF The present invention relates to multiple crystalline forms of a pharmaceutically acceptable salt of a compound N-cyclopropyl-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyri din-3-yl)methyl)piperazin-1-yl)picolinamide, a preparation metho...
WO/2024/042448A1	AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB The main objective of the present invention is to improve the process for the preparation of ruxolitinib using protected (E)-N-(3-(Dimethylamino)-2-(7H- pyrrolo[2,3-d] pyrimidin-4-yl) allylidene)-N-methylmethanaminium chloride hydrochlor...
WO/2024/041606A1	COMPOUND WITH ANTI-KRAS MUTANT TUMOR ACTIVITY The present invention provides a compound represented by formula (I) for use as a KRAS inhibitor, a pharmaceutical composition comprising the compound, a method for preparing the compound, and use of the compound in treating a cancer.
WO/2024/044570A1	COMPOUNDS AND METHODS FOR MODULATING HER2 Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein R1, R2, A, E1, E2, and G are as described in any of the embodiments described in this disc...
WO/2024/044757A1	AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS The present disclosure provides compounds and compositions that are useful as MYC protein modulators and methods of using the same for treating MYC-mediated diseases or disorders.
WO/2024/042119A1	PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRROLOPYRIMIDINES AND INTERMEDIATES There is provided a new and improved synthetic route for the synthesis of the compound 1-{2-[(1R)-1-aminoethyl]-4-chlorobenzyl}-2-thioxo-1,2,3,5-te trahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one (Formula (I)) that is readily scalable for comm...
WO/2024/037527A1	BTK DEGRADING COMPOUNDS Provided herein are heteroaromatic compounds which target BTK proteins for ubiquitination and proteasomal degradation. Also provided herein are methods for using said compounds for the treatment of diseases.
WO/2024/040190A1	INDANE AND COUMARAN DERIVATIVES AS FAST SKELETAL MUSCLE MYOSIN INHIBITORS Provided are compounds of Formula (I). Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formu...
WO/2024/040267A2	DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF The present disclosure is directed to N-(3-substituted-chroman-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4- amine compounds useful as PINK1 modulators, compounds useful in preparing N-(3-substituted-chroman-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4- ami...
WO/2024/039883A2	COMPOSITIONS AND METHODS TO TREAT MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS Compositions useful for treating a subject suffering from a myeloproliferative disorder or disease, or from a disease or condition associated with myeloproliferative neoplasms, and methods of such treatment using the compositions, wherei...
WO/2024/039886A1	BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT Benzazepine derivatives of Formula (I), compositions comprising therapeutically effective amounts of those benzazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with ce...
WO/2024/038131A1	INHIBITORS OF MYELOPEROXIDASE The specification generally relates to compounds of Formula (I), (Ia), and (Ib) and pharmaceutically acceptable salts thereof, where X, Y1, Y2, Y3, Y4, and Y5 and X1, X2, r, and q, have any of the meanings defined herein, together with c...
WO/2024/037667A2	FUSED RING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Disclosed are a fused ring heterocyclic compound represented by the following formula I, an optical isomer, a deuterated substance, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the subs...
WO/2024/039767A1	IMIDAZO[1,2-B]PYRIDAZINE INHIBITORS OF CYCLIN-DEPENDENT KINASES Disclosed are inhibitors for cyclin-dependent kinase 12 or 13 (CDK12/13) of Formula I comprising imidazo[1,2-b]pyridazine core, and uses thereof. Methods of using the compounds, or pharmaceutical compositions comprising compounds, to tre...
WO/2024/037396A1	CRYSTAL FORM OF PYRAZOLOPYRIMIDINE ESTER COMPOUND AND PREPARATION METHOD THEREFOR Provided is a crystal form (Form II) of a pyrazolopyrimidine ester compound having a structure as shown in formula (I). The crystal form is characterized by a powder X-ray diffraction pattern, differential scanning calorimetry and infrar...
WO/2024/040080A1	KRAS INHIBITOR CONJUGATES The present embodiments provide compounds of Formula I, compositions of the compounds, and methods for treating diseases such as cancer.
WO/2024/039903A2	CDK2 INHIBITORS AND USES THEREOF The present invention provides compounds, compositions thereof, and methods of using the same.
WO/2024/038398A1	NOVEL SALT OF SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND ITS USES The present invention provides a novel 5-fluoro-1-[(2-fluorophenyl) methyl]-1H-pyrazolo [3, 4-b] pyridine-3-carboximidamide formate compound of formula (IV) and process for preparation thereof. The present invention further provides for ...
WO/2024/039842A2	INHIBITORS OF TAM RECEPTORS Disclosed are compounds of formula (I):, Variables R1-R4, X1-X6, and Het are defined herein. Also disclosed are a pharmaceutical composition containing such a compound and methods of using the compound to treating disorders associated wi...
WO/2024/038356A1	SYNTHESIS OF SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS AND SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND ANALOGUES THEREOF The present disclosure includes synthetic methods for preparing certain substituted 1-aryl-1'-heteroaryl and 1,1'-biheteroaryl compounds, which can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) infections in a pati...
WO/2024/040109A2	KRAS INHIBITORS The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
WO/2024/037392A1	CRYSTAL FORM OF PYRAZOLOPYRIMIDINE ESTER COMPOUND AND PREPARATION METHOD THEREFOR Provided is a crystal form Form I of a pyrazolopyrimidine ester compound having a structure as shown in formula (I). The crystal form is characterized by a powder X-ray diffraction pattern, a differential scanning calorimetry method, the...
WO/2024/038818A1	FUSED-RING POLYAZAACENE COMPOUND, AND PHOTOELECTRIC CONVERSION ELEMENT OR ORGANIC ELECTRONIC ELEMENT CONTAINING SAME Provided are: a fused-ring polyazaacene compound capable of having a dramatically improved hole transport capability; and an organic electronic element comprising the fused-ring polyazaacene compound.　A material for a photoelectric con...
WO/2024/032598A1	TGF-β INHIBITOR COMPOUND AND USE THEREOF The present application relates to a TGF-β inhibitor compound and the use thereof. Specifically, disclosed in the present application is a compound as represented by formula (I), or an isotope-labeled compound thereof, or an optical iso...
WO/2024/034593A1	HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN Provided is a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and/or lung cancer.　The present inventors examined compounds useful as an active ingredient of a pharmaceutical compos...
WO/2024/036270A1	KRAS INHIBITORS The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
WO/2024/033668A1	NOVEL AVAPRITINIB SALTS AND METHODS FOR PREPARING THE SALTS Novel avapritinib salts and methods for preparing the salts The present invention relates to new citrate and napsylate salts of avapritinib, their crystalline forms and processes for their preparation.
WO/2024/032647A1	PREPARATION METHOD FOR NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITOR, AND APPLICATION AND USE THEREOF The present invention relates to a nitrogen-containing heterocyclic compound as a ubiquitin-specific protease 1 inhibitor, a preparation method therefor, and use thereof. In particular, the present invention relates to a compound represe...
WO/2024/035771A2	ULK3 INHIBITORS AND USES THEREOF The present disclosure provides compounds of Formula (I), Formula (II) and Formula (III) which are useful as inhibitors of ULK3 and methods of using the same to treat cancers, such as ULK-associated cancers, for example multiple myeloma ...
WO/2024/032661A1	KIF18A INHIBITOR AND USE THEREOF The present invention relates to the technical field of medicine, in particular to a KIF18A inhibitor compound, a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer thereof, a pharmaceutical composition and prep...
WO/2024/031306A1	DUAL-LUCIFERASE REPORTER GENE DETECTION SYSTEM AND USE THEREOF Provided are a dual-luciferase reporter gene detection system and use thereof. The detection system comprises Gaussia luciferase, Pleuromamma xiphias luciferase, and a substrate, and the substrate is coelenterazine or a derivative thereo...
WO/2024/032589A1	TGF-β INHIBITOR COMPOUND AND USE THEREOF Provided are a TGF-β inhibitor compound and use thereof. In particular, provided is a compound represented by formula (I) or formula (II) or an isotopically labeled compound, an optical isomer, a geometric isomer, a tautomer, an isomer ...
WO/2024/035950A1	INHIBITORS OF KIF18A AND USES THEREOF Provided are compounds of the Formula (I), or pharmaceutically acceptable salts thereof, which are useful for the inhibition of KIF18A and in the treatment of a variety of KIF18A mediated conditions or diseases, such as cancer.
WO/2024/033282A1	MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES The present invention relates to a heterocyclic compound of formula (1) as well as compositions and devices comprising these compounds, especially organic electroluminescent devices comprising these compounds as host materials.

Matches 151 - 200 out of 33,986	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >